the methods. A review of this point would again potentially help to inform future work.
Minor considerations: 6.
Page 2, Line 45, Limitations: The final sentence containing "and the number of ICUs recruited in order to achieve 150 participating ICUs" is somewhat confusing if the reader has not reviewed the manuscript in its entirety. I would suggest clarifying this point along the lines of discussion on this subject later in the manuscript (i.e., page 11). 7.
Page 4, Line 26, Introduction: Additional detail about current evidence-based practice for MV weaning and separation would help to improve the introduction. 8.
Page 8, Lines 34 -40, Sample Size Estimation: The authors should clarify whether the clinical assumptions underlying the sample size calculations are evidence based (and provide references) or stemmed from clinician consensus judgement.
Introduction
Overall, I believe the authors have framed the need for this investigation well, as there is truly a paucity of data regarding how weaning is actually done on an international scale. But I believe the Introduction would be strengthened by stating how critically ill patients could be benefited by the conduct of this study, as there is little rationale to conduct an observational study (especially of this magnitude) if there is no intent on using the observational data to target interventions that will improve outcome downstream. I'm sure this group of authors has this in mind-I personally would state something to this effect in the Intro.
Objectives I would include the hypothesis (es) related to these objectives in this section.
Study population
Please clarify what is meant by excluding patients who reside in participating ICUs for >24 hours on the first day of data collection..... Does that mean that patients who have been in the ICU for more than 1 day will be excluded?
Study outcomes
Please clarify what is meant by "direct extubation". Is that extubation with no breathing trial? With respect to the outcomes, since an association between MV discontinuation practices and these outcomes will be sought, will you also capture other data known to influence these outcomes (illness severity, sedation, co-morbid conditions, etc)? If so, please provide the data that you will capture. Phase 1 How successful was the process of enclosing an information card and return envelope?
Phase 3 Can you give a general estimation of when the study will begin and when it will end? I know that there will be a lot of overlap because so many ICUs are involved, but it would be nice to have an idea of when the study is launching.
Sample Size Estimation
What are these estimations based on ? Please provide citations and/or rationale here. Please provide the 16 pre-specified variables.
Discussion
Similar to above, can you be more specific on the variables that will be collected to define "sedation" and "mobilization" practices. Perhaps a personal preference, but I think the stated hypotheses would be better served in the Objectives sections. I'm curious why the use of HME is postulated to be associated with more initial SBT failures.
For completeness sake, I would include some mention of the Limitations of this work.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Craig Jabaley Institution and Country: Emory University, United States Please state any competing interests or state 'None declared': None declared
Please leave your comments for the authors below
The authors have submitted a protocol for a prospective study examining practices around the discontinuation of mechanical ventilation (MV) in an international population of critically ill adults. Although anecdotally perceived to be highly variable, there is scant evidence available to more definitively assess variability in this practice. As mentioned by the authors, weaning and separation from MV is an important topic with implications for relevant clinical outcomes. This study builds upon prior international survey work. Generally speaking, the submitted protocol is relatively concise and parsimonious. I have suggested a few areas that would benefit from expansion and additional clarity.
Major considerations: 1.General: How did the investigators overcome both differences in international and device/manufacturer-specific terminology related to modes of mechanical ventilation? Further detail here may help to inform future work.
For all studies in my program of research on mechanical ventilation discontinuation we have used a series of papers on ventilator taxonomy by Chatburn et al (Respir Care. 1992 , Respir Care. 2001 , Respir Care. 2007 , Respir Care. 2012 , Respir Care. 2014 to standardize ventilator taxonomy.
To address variation in terminology across regions, we engaged ALL regional site leads (one per region) as collaborators in developing the study protocol and developing and refining the Case Report Forms (CRFs). This was tremendously helpful in ensuring that the terminology (mechanical ventilation, modes, methodology and training-related) we used in the IOS study was applicable to participating ICUs in the 6 regions in which we implemented the study.
After development, we pilot tested the CRFs in several regions (e.g., Can, UK) with individuals who were not directly involved in the data collection process to assess the clarity of the CRFs and ensure that we to ensure that we could capture the desired data in a uniform manner.
2.General: Were attempts planned or undertaken to account for variability in the mechanical ventilators utilized in each intensive care unit? For example, some units may utilize ventilators equipped with partially or fully automated proportional assist modes and others not. It would be of interest to ascertain if utilization of advanced weaning modes is uncommon despite them being available to clinicians, for example.
We did not capture data related to specific ventilators available in each ICU as this was not part of our research questions. Our research questions, prioritized capturing data related to clinical practices, regardless of the equipment available. Consequently, we focused on weaning practices and patient care practices (sedation, mobilization etc) during weaning. At a site level, we collected data regarding participating sites, patient volume, turnover, personnel, and practices on the Site Formsee CRFs (now included as on-line supplements)
To address the reviewers concern, we recorded modes of MV used before initial attempts at discontinuation (direct extubation, direct tracheostomy, initial SBT)-see forms Appendices 3 , 4, and 5 respectively.
When recording PS levels, we standardized data collection by specifying that we were interested in the PS level above PEEP. As per our response above, the terminology used was decided through discussion and consensus with the regional site leads.
Our goal was to identify care practices with important variation that could be subsequently addressed in future (intervention or dissemination) trials.
3.Methods: Broadly, description of the data to be collected is relatively scant. This may negatively impact a reader wondering whether relevant covariates of interest will be captured. These could include use of non-invasive respiratory support after extubation, sedation strategies, trainee presence, etc. A table or supplement would be informative. This is an excellent point. Thank you for this suggestion.
In the protocol manuscript, we aimed to provide a broader overview of the study objectives, planned methods, and analyses.
Based on your comment, we have added all study CRFs as appendices to the manuscript. Attaching the CRFS will provide readers with the granular data that they require to interpret our findings. For each patient in the IOS study, we collected 3 types of data: baseline/ICU admission data, data at the time of the initial attempt at MV discontinuation, and outcomes). For each participating ICU, we collected information regarding participating sites and their 'practices of care' on a separate Site Form.
We modified the paragraph under Phase 2 to reference relevant appendices:
Research staff will prospectively screen the ICU on a daily basis for eligible study patients and record all patients in screening logs (Appendix 1). After identification of eligible patients, research personnel will follow patients prospectively to ascertain the initial strategy that facilitated MV discontinuation. We will develop web-based data forms to tabulate demographic data (Appendix 2), data at the time of ICU admission (Appendix 2), and discontinuation events (direct extubation (Appendix 3), direct tracheostomy (Appendix 4) , initial successful SBT and up to 2 subsequent SBTs (Appendices 5a,5b,5c), initial failed SBT and up to 2 subsequent SBTs (Appendices 5a,5b,5c), or death before any attempt at discontinuation can be made (Appendix 6)). Demographic and ICU admission data will be entered each time a patient meets eligibility criteria. Finally, we will collect information regarding patient outcomes (Appendix 7) and relevant processes of care [the presence of weaning and SBT protocols, the use of daily screening, and personnel (e.g., RTs, nurses, kinesiotherapists or others) involved in weaning] in participating ICUs on separate outcomes (Appendix 7) and site forms (Appendix 8), respectively. Research personnel complete paper data collection forms and enter data into the Medidata RAVE System™ (Medidata Solutions, New York, USA). 4.Methods: Anticipated dates for the study are not included.
We did not include specific dates as we anticipate wide variation in the time that would be required to obtain regional ethics approval and the time required to finalize contracts with each of the 142 committed participating ICUs. Morevoer, we anticipate that sites may drop out for various reasons and that recruitment may be an iterative process. This is particularly important as we are NOT limiting participation to academic centres in the IOS study. As such, we anticipate that some centres (especially in community hospitals and in specific regions) may not have well organized research infrastructure. Moreover, in some regions multiple approvals will be required (central ethics, Caldicott, R & D approval) and that these approvals will occur in series rather than in parallel.
We plan to report the time required to obtain ethics approval and for contract execution in a separate manuscript. A separate grant has been secured for this substudy. We anticipate that the time to site activation will largely depend on the time that it takes to obtain ethics approval(s) and to finalize contracts. We plan to report the actual data collection period in the full manuscript publication. 5.Page 10, Line 19, Discussion: Mention of patient-level data validation is made here without corresponding elucidation in the methods. A review of this point would again potentially help to inform future work.
Thank you again for this comment. We have modified the text to characterize how we reviewed, queried, and addressed items that were nonsensical, unclear, or were 'out of sequence' (e.g., dates that were not in a logical order).
MODIFICATION MADE:
We have changed the wording as follows: "A study of this scope and rigor focused on MV discontinuation in both academic and community ICUs, involving individual site-training, prospective screening log completion, event identification and data collection, and patient-level data validation (through a process involving individual data review, and detailed query generation and resolution over electronic mail and within Medidata RAVE™) has not been conducted previously."
Minor considerations:
6. Page 2, Line 45, Limitations: The final sentence containing "and the number of ICUs recruited in order to achieve 150 participating ICUs" is somewhat confusing if the reader has not reviewed the manuscript in its entirety. I would suggest clarifying this point along the lines of discussion on this subject later in the manuscript (i.e., page 11).
Thank you for this comment. We have changed the word as follows:
OLD WORDING: Unanticipated challenges included the need to obtain prospective consent by a small number of research ethics boards, large variation in time to ethics and contract approvals, and the number of ICUs recruited in order to achieve 150 participating ICUs. NEW WORDING: Challenges will include the need to obtain prospective consent by a small number of research ethics boards, variation in time to ethics and contract approvals, and the number of ICUs that we will need to recruit to achieve our target number of participating ICUs. 7.Page 4, Line 26, Introduction: Additional detail about current evidence-based practice for MV weaning and separation would help to improve the introduction.
We have included several references (11 in total) regarding evidence-based MV discontinuation in the following paragraph.
Randomized controlled trials, meta-analyses, and clinical practice guidelines support the use of specific strategies during weaning including the early identification of weaning candidates using weaning protocols [6] [7] [8] [9] , tests to determine the patient's ability to breathe spontaneously [or spontaneous breathing trials (SBTs)] [10-13], and selected modes of ventilation or strategies [Pressure Support (PS) and SBTs (using PS or T-piece) [14-16].
8.Page 8, Lines 34 -40, Sample Size Estimation: The authors should clarify whether the clinical assumptions underlying the sample size calculations are evidence based (and provide references) or stemmed from clinician consensus judgement.
The sample size estimates were based on 'clinician estimates'. Where we did not state 'we estimated'…..in the corresponding text, we now state based on clinician judgment…. OLD WORDING: We will collect data on at least 10 non-death discontinuation events within each participating ICU to obtain at least 1,500 non-death discontinuation events. We anticipate that at least 50% of discontinuation events will involve an initial SBT [expected range 750-1050 SBTs]. NEW WORDING: We will collect data on at least 10 non-death discontinuation events within each participating ICU to obtain at least 1,500 non-death discontinuation events. Based on clinical judgement, we anticipate that at least 50% of discontinuation events will involve an initial SBT [expected range 750-1050 SBTs].
Please note that we also identified an error which has now been corrected: the following text should read 18 (as opposed to 16) prespecified variables.
We have included Appendix 9 as an on-line supplement. This appendix lists the prespecified predictor variables.
Thank you for your review of our protocol manuscript. We appreciate your comments and suggestions.
Reviewer: 2 Reviewer Name: Brian M Fuller Institution and Country: Washington University in St. Louis St. Louis, MO USA Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below This study will generate some very interesting data, and is extremely pertinent in the day-to-day practice of an intensive care unit. This is important work and this was a nice peer review process to participate in.
My suggestions are minor, and are mostly related to clarity and transparency of the data that will be collected. These could easily be attached in a table or in a supplement to the main manuscript. I think it would improve transparency in reporting here.
Examples are the following:
Please clarify what is meant by "time-dependent factors" and what you will actually collect with respect to this data.
Thank you for this comment.
On each of the event forms (direction extubation, direct tracheostomy and initial SBT)see Appendices 3, 4, and 5 respectively (now included as on line supplements), we asked whether selected conditions developed AFTER patients met our study inclusion criteria and BEFORE they experienced an initial discontinuation event. This section is entitled 'Course in Hospital' on each of the relevant appendices (pertaining to discontinuation events). For example, we recorded for individual patients whether they developed ARDS, or AKI requiring dialysis, or AKI not requiring dialysis, or critical illness polyneuropathy, etc. We considered these events to be of potential prognostic import in addition to baseline variables in the planned Cox proportional hazards analysis.
Secondary and Tertiary Objectives: We will use Cox Proportional Hazards modeling to explore the relationship between patient characteristics and time dependent factors (clinical conditions that developed after enrollment and before initial discontinuation events) associated with the use of selected discontinuation strategies.
MODIFIED TEXT
Research staff will prospectively screen the ICU on a daily basis for eligible study patients and record all patients in screening logs (Appendix 1). After identification of eligible patients, research personnel will follow patients prospectively to ascertain the initial strategy that facilitated MV discontinuation. We will develop web-based data forms to tabulate demographic data (Appendix 2), data at the time of ICU admission (Appendix 2), and discontinuation events (direct extubation (Appendix 3), direct tracheostomy (Appendix 4) , initial successful SBT and up to 2 subsequent SBTs (Appendix 5a-c), initial failed SBT and up to 2 subsequent SBTs (Appendices 5a-c), or death before any attempt at discontinuation can be made (Appendix 6)). Demographic and ICU admission data will be entered each time a patient meets eligibility criteria. Finally, we will collect information regarding patient outcomes (Appendix 7) and relevant processes of care [the presence of weaning and SBT protocols, the use of daily screening, and personnel (e.g., RTs, nurses, kinesiotherapists or others) involved in weaning] in participating ICUs on separate outcomes (Appendix 7) and site forms (Appendix 8), respectively. Research personnel complete paper data collection forms and enter data into the Medidata RAVE System™ (Medidata Solutions, New York, USA).
When "predictors" are mentioned (under 'Tertiary Objecives'), what data will be collected with respect to clinician, patient, SBT, institutional, and regional.
Please describe the ICUs better, as it is not entirely clear how one will describe academic vs. community, staffing, etc. What data will actually be collected here?
Introduction
We discuss relevance in the Abstract and Discussion sections of the protocol manuscript.
ABSTRACT "This study will characterize variation in practice related to MV discontinuation internationally and the association of using different discontinuation strategies on clinically important outcomes."
DISCUSSION:
OLD WORDING "The IOS Study will provide valuable information to the international critical care community, foster a collaborative network of investigators interested in MV discontinuation, lay the foundation for future knowledge translation studies to reduce avoidable variation in weaning practice, and promote future collaborations between investigators and industry partners."
We agree that a key benefit that is expected to arise from conduct of this study is the identification of practices (within and across regions) that warrant further study.
MODIFICATION MADE:
We modified the relevance section of the DISCUSSION to better reflect this important point as follows:
NEW WORDING The IOS Study will provide valuable information to the international critical care community, identify practices that warrant further study, inform the design of future intervention and dissemination studies, and foster collaborations between investigators and regions.
In initial drafts of the protocol manuscript, we had included the hypotheses immediately after the objectives. However, after review of the manuscript by the coinvestigators, several investigators requested that the hypotheses be moved to the Discussion section of the manuscript as they found it distracting when presented early on in the protocol manuscript. **If the editorial team has a strong preference, I would be happy to relocate this information.
Study population
Yes. This is correct. We focused on newly admitted patients to ICUs with the time clock beginning after each site was trained (WebEx teleconferencing) on the protocol and CRF completion and subsequently activated. We did this in the spirit of conducting a true prospective observational study to ensure that 'sbts' (for example) were not missed in a previous hospital or the current ICU if patients were transferred from another ICU to the index (participating) ICU.
Study outcomes
Please clarify what is meant by "direct extubation". Is that extubation with no breathing trial? Correct. NO prior SBT. MODIFICATION MADE. To enhance the clarity of the manuscript, we modified the Introduction after first mention of our classification of 'discontinuation events' as follows:
"However, little is known about how clinicians actually discontinue MV [direct extubation (no prior SBT), initial SBT, direct tracheostomy] in practice or about the impact of different discontinuation practices on clinical outcomes. [17] "
With respect to the outcomes, since an association between MV discontinuation practices and these outcomes will be sought, will you also capture other data known to influence these outcomes (illness severity, sedation, co-morbid conditions, etc)? If so, please provide the data that you will capture.
We will use Cox Proportional Hazards modeling to explore the relationship between patient characteristics and time dependent factors associated with the use of selected discontinuation strategies.
MODIFIED TEXT Secondary and Tertiary Objectives: We will use Cox Proportional Hazards modeling to explore the relationship between patient characteristics and time dependent factors (clinical conditions that developed after enrollment and before initial discontinuation events) associated with the use of selected discontinuation strategies.
We have now included the CRFs (baseline characteristics -Appendix 2). Time dependent factors are listed under Course in Hospital (direct extubation, direct tracheostomy, and initial SBT forms -Appendices 3, 4, and 5 respectively).
Phase 1
How successful was the process of enclosing an information card and return envelope?
Although we have not conducted a formal analysis, approximately 60% of the sites that we included in the Observational Study completed the information card enclosed within the International Weaning Survey.
Phase 3
Can you give a general estimation of when the study will begin and when it will end? I know that there will be a lot of overlap because so many ICUs are involved, but it would be nice to have an idea of when the study is launching.
We plan to report dates reflecting initiation and completion of data collection in the final manuscript.
Sample Size Estimation
We have corrected 16 pre-specified variables to 18 pre-specified variables.
We have changed the wording as follows:
We will collect data on at least 10 non-death discontinuation events within each participating ICU to obtain at least 1,500 non-death discontinuation events. Based on clinical judgement, we anticipate that at least 50% of discontinuation events will involve an initial SBT [expected range 750-1050 SBTs].
Members of the investigative team prioritized these variables in a teleconference a priori. These variables are now appended (Appendix 9).
Thank you for this suggestion.
Discussion
Similar to above, can you be more specific on the variables that will be collected to define "sedation" and "mobilization" practices.
Given space constraints, we have included the individual CRFs (Appendices) in the on-line supplement. In the Discontinuation Event Forms (Appendices 3, 4, and 5 you will see how we collected sedation and mobilization practices prior to discontinuation events. Perhaps a personal preference, but I think the stated hypotheses would be better served in the Objectives sections.
Thank you for this comment. Reviewer 1 also made this comment.
We included the limitations at the front along with the strengths as per the requirements for preparation of protocol manuscripts.
Thank you for your thoughtful review of our protocol.
VERSION 2 -REVIEW

REVIEWER
Craig Jabaley Emory University Atlanta, GA, USA REVIEW RETURNED 24-Jul-2019
GENERAL COMMENTS
Many thanks to the authors for their review of prior feedback and revisions to the manuscript. I have a few minor additional points for consideration below that should be considered optional revisions to the final manuscript.
1. Regarding prior work concerning standardized ventilator taxonomies and the authors' experience in this domain, addition of a brief discussion with reference to the Chatburn publications would likely be of interest and value to the reader.
2. Regarding challenges surrounding lack of research infrastructure at community hospitals and in certain regions, the authors' plan for a related follow-up study is laudable. Concerning the manuscript under consideration at present, it would likely be of interest to readers without experience conducting large clinical studies to include a brief clarification/discussion around this point. Exclusion of community centers, for example, from large prospective observational and clinical studies is a common point of criticism but often rooted in pragmatism on the part of the investigators.
3. General comment: From my standpoint, inclusion of hypotheses in the Discussion is acceptable acknowledging variety in the formatting of published protocols. 
REVIEWER
